实体癌的抗体免疫疗法：进展与前景
Antibody-based immunotherapy of solid cancers: progress and possibilities.
作者信息
Nicodemus Christopher F
机构信息
AIT Strategies, POB 429 Sunset Lane, Franconia, NH 03580, USA.
出版信息
Immunotherapy. 2015;7(8):923-39. doi: 10.2217/imt.15.57. Epub 2015 Aug 28.
Abstract
Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets for antibody development. The clinical success of the checkpoint inhibitors has validated immune modulation and mobilization as a therapeutic approach. Solid cancers are distinguished from hematologic malignancies because the solid tumor stroma contains significant tumor promoting and immune dampening elements less prominent in hematologic cancer. This review highlights how engineered monoclonal antibody products are emerging as potential cornerstones of new more personalized cancer treatment paradigms that target both tumor and the stromal environment.
摘要
单克隆抗体仍然是新型癌症治疗的主要产品选择。抗体的特性是抗原特异性和所包含恒定区的函数。对癌症生物学和宿主-肿瘤相互作用的分子理解的迅速进展，为抗体开发确定了一系列新的靶点。检查点抑制剂的临床成功验证了免疫调节和动员作为一种治疗方法的有效性。实体癌与血液系统恶性肿瘤不同，因为实体瘤基质含有显著的肿瘤促进和免疫抑制成分，而这些成分在血液系统癌症中不那么突出。本综述强调了工程单克隆抗体产品如何正在成为新的、更个性化的癌症治疗模式的潜在基石，这些模式同时针对肿瘤和基质环境。
相似文献
1
Antibody-based immunotherapy of solid cancers: progress and possibilities.实体癌的抗体免疫疗法：进展与前景
Immunotherapy. 2015;7(8):923-39. doi: 10.2217/imt.15.57. Epub 2015 Aug 28.
2
Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.利用免疫系统对抗癌症：当前的免疫疗法方法和治疗靶点。
Mol Biol Rep. 2021 Dec;48(12):8075-8095. doi: 10.1007/s11033-021-06752-9. Epub 2021 Oct 20.
3
Immunotherapy for small-cell lung cancer: emerging evidence.小细胞肺癌的免疫疗法：新出现的证据。
Future Oncol. 2016 Apr;12(7):931-43. doi: 10.2217/fon-2015-0012. Epub 2016 Feb 17.
4
[Cancer immunotherapy: Rational and recent breakthroughs].[癌症免疫疗法：原理与近期突破]
Rev Med Interne. 2016 Oct;37(10):694-700. doi: 10.1016/j.revmed.2016.05.023. Epub 2016 Jun 28.
5
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.抗PD-L1和抗PD-1药物在癌症治疗中的现状。
Mol Immunol. 2015 Oct;67(2 Pt A):4-17. doi: 10.1016/j.molimm.2015.02.009. Epub 2015 Mar 5.
6
[Immunotherapy in lung cancer: New concepts].[肺癌中的免疫疗法：新概念]
Rev Mal Respir. 2018 Jun;35(6):642-651. doi: 10.1016/j.rmr.2018.03.001. Epub 2018 Jun 23.
7
Immunotherapy and the concept of a clinical cure.免疫疗法和临床治愈的概念。
Eur J Cancer. 2013 Sep;49(14):2965-7. doi: 10.1016/j.ejca.2013.06.019. Epub 2013 Jul 25.
8
Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.用于实体瘤免疫治疗的细胞因子、趋化因子和共刺激融合蛋白。
Handb Exp Pharmacol. 2008(181):291-328. doi: 10.1007/978-3-540-73259-4_13.
9
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.免疫检查点蛋白：癌症治疗的新范例——临床前背景：CTLA-4 和 PD-1 阻断。
Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005.
10
Immunotherapy in Tumors.肿瘤免疫疗法
Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809.
引用本文的文献
1
Therapeutic Monoclonal Antibodies against Cancer: Present and Future.治疗性单克隆抗体治疗癌症：现状与未来。
Cells. 2023 Dec 14;12(24):2837. doi: 10.3390/cells12242837.
2
The relationship between autophagy and PD-L1 and their role in antitumor therapy.自噬与程序性死亡受体 1 配体（PD-L1）之间的关系及其在抗肿瘤治疗中的作用。
Front Immunol. 2023 Mar 15;14:1093558. doi: 10.3389/fimmu.2023.1093558. eCollection 2023.
3
Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.针对新生抗原治疗实体恶性肿瘤：免疫手术。
Front Immunol. 2021 Jul 15;12:592031. doi: 10.3389/fimmu.2021.592031. eCollection 2021.
4
Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.针对间皮素上的膜近端表位可增强双特异性抗体阻断间皮素阳性肿瘤上 CD47 的肿瘤杀伤活性。
MAbs. 2020 Jan-Dec;12(1):1739408. doi: 10.1080/19420862.2020.1739408.
5
Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor-An Opportunity for Cancer Treatment.纳米医学靶向 TNFR2 和 DNA 去甲基化抑制剂的协同作用——癌症治疗的新机会。
Cells. 2019 Dec 20;9(1):33. doi: 10.3390/cells9010033.
6
Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists.助力释放的守护者：支持HDM2（MDM2）拮抗剂抗癌活性的药物组合。
Cancers (Basel). 2019 Jul 19;11(7):1014. doi: 10.3390/cancers11071014.
7
Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis.骨髓肥大细胞抗体可靶向细胞表面蛋白在系统性肥大细胞增多症中的表达谱。
Int J Mol Sci. 2019 Jan 28;20(3):552. doi: 10.3390/ijms20030552.
8
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.靶向血管生成因子的反义寡核苷酸作为潜在的癌症治疗药物
Mol Ther Nucleic Acids. 2019 Mar 1;14:142-157. doi: 10.1016/j.omtn.2018.11.007. Epub 2018 Nov 20.
9
Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation.肿瘤微环境中基质细胞对转移起始的影响。
Int J Biol Sci. 2018 Nov 13;14(14):2083-2093. doi: 10.7150/ijbs.25720. eCollection 2018.
10
The challenges of checkpoint inhibition in the treatment of multiple myeloma.在多发性骨髓瘤治疗中抑制检查点所面临的挑战。
Cell Immunol. 2018 Dec;334:87-98. doi: 10.1016/j.cellimm.2018.10.003. Epub 2018 Oct 13.
本文引用的文献
1
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors.靶向吲哚胺2,3-双加氧酶1/色氨酸2,3-双加氧酶及其下游效应分子的癌症免疫疗法
Front Immunol. 2015 Jan 12;5:673. doi: 10.3389/fimmu.2014.00673. eCollection 2014.
2
The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.抗HER3抗体帕妥珠单抗可消除由神经调节蛋白介导的结直肠癌细胞对西妥昔单抗的耐药性。
Oncotarget. 2014 Dec 15;5(23):11847-56. doi: 10.18632/oncotarget.2663.
3
Nivolumab in previously untreated melanoma without BRAF mutation.纳武利尤单抗治疗未经 BRAF 突变检测的初治黑色素瘤。
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
4
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.腺苷A2A受体的髓系表达抑制实体瘤微环境中的T细胞和自然杀伤细胞反应。
Cancer Res. 2014 Dec 15;74(24):7250-9. doi: 10.1158/0008-5472.CAN-13-3583. Epub 2014 Nov 6.
5
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.派姆单抗治疗伊匹单抗难治性晚期黑色素瘤的抗程序性死亡受体 1 治疗：一项 I 期试验的随机剂量比较队列。
Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.
6
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny.树突状细胞、单核细胞和巨噬细胞：基于发生的统一命名法。
Nat Rev Immunol. 2014 Aug;14(8):571-8. doi: 10.1038/nri3712. Epub 2014 Jul 18.
7
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
8
Tim-3: an emerging target in the cancer immunotherapy landscape.TIM-3：癌症免疫治疗领域的新兴靶点。
Cancer Immunol Res. 2014 May;2(5):393-8. doi: 10.1158/2326-6066.CIR-14-0039.
9
IL-10: master switch from tumor-promoting inflammation to antitumor immunity.白细胞介素-10：从促进肿瘤炎症到抗肿瘤免疫的主开关。
Cancer Immunol Res. 2014 Mar;2(3):194-9. doi: 10.1158/2326-6066.CIR-13-0214.
10
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.帕尼单抗对比西妥昔单抗治疗化疗耐药野生型 KRAS 外显子 2 转移性结直肠癌患者（ASPECCT）：一项随机、多中心、开放标签、非劣效性的 3 期研究。
Lancet Oncol. 2014 May;15(6):569-79. doi: 10.1016/S1470-2045(14)70118-4. Epub 2014 Apr 14.
Zotero 插件